Bernstein reiterates Market Perform rating on HCA Healthcare stock

HCA Healthcare delivered robust Q2 2025 results, exceeding EPS and revenue forecasts, with adjusted EBITDA 4% above consensus despite slower patient volumes, while actively pursuing AI-driven digital transformation for efficiency. Analyst sentiment is mixed, with Bernstein and RBC Capital raising price targets to $417 and $449, respectively, maintaining neutral-to-positive ratings, but Wolfe Research downgraded HCA to Peerperform due to concerns regarding multi-year payer mix pressures from 2026.

Analysis

HCA Healthcare (HCA) demonstrated robust operational strength in its second-quarter 2025 results, outperforming market expectations despite a noted slowdown in patient volumes. The company reported earnings per share of $6.84, significantly above the $6.27 forecast, and revenue of $18.61 billion, which narrowly beat the consensus of $18.49 billion. This financial outperformance is further evidenced by an adjusted EBITDA of $3,849 million, exceeding consensus estimates by 4%. Strategically, the company is focusing on long-term efficiency gains through its Digital Transformation and Innovation (DT&I) unit, which aims to leverage AI and machine learning to reduce administrative friction and support clinical decisions. However, the positive financial metrics are tempered by a mixed analyst outlook. While RBC Capital raised its price target to $449, citing industry-leading margins, and Bernstein SocGen Group moved its target to $417, Wolfe Research downgraded the stock to Peerperform. This downgrade is predicated on significant future risks, specifically potential multi-year payer mix pressure stemming from Exchange dynamics in 2026 and Provider Tax changes anticipated in 2028, creating a clear tension between current performance and long-term headwinds.

Key Decisions for Investors

• Investors should weigh HCA's demonstrated Q2 2025 earnings outperformance and operational efficiency against the specific, medium-term headwinds of payer mix and provider tax pressures.
• Closely monitor developments related to payer mix, particularly Exchange enrollment trends for 2026 and state-level discussions on provider taxes, as these are the primary risks cited in the recent downgrade.
• Evaluate the progress and impact of the company's AI-driven digital transformation strategy, as its success in improving efficiency may be critical to offsetting the identified future margin pressures.